Cannabinoid Research Firm Cannabis Science, Inc. Could Go Under
By Anne Holland [Updated as of 4/25/12] According to its annual 2012 report filed today, Cannabis Science, Inc. (PINK:CBIS), may be in danger of shutting its doors. The company’s Form 10-K stated, “At this time, our ability to generate any significant revenues continues to be uncertain. There is substantial doubt about our ability to continue as a going concern.” Although this type of doom-saying is normal for financial filings, which must include worst-case scenarios, Cannabis Science’s financials, as presented, do not appear to be encouraging. The company’s stock has been hovering just over 5 cents all day, compared to nearly 11 cents a year ago.
Despite this uncertainty, the company, which develops cannabinoid-based (CBD) therapies for the treatment of cancer and infectious diseases, is continuing to fight on. Just last month, it announced the appointment of another member of its scientific advisory board, Michael McGrath, a professor of medicine and lab medicine at the University of California, San Francisco. As we’ve reported in the past, credible medical studies have shown that CBDs may be effective in fighting some forms of cancer. The overall future of CBD-based treatments may be very bright indeed … but the legal situation surrounding them is still murky.
Although Cannabis Science only has two full-time employees, its general and administrative expenses increased by more than $1.2 million during 2012, from $3 million to $4.3 million, largely due to management and consulting fees owed under purchase agreements related to its acquisitions of GGECO University Inc and Cannabis Consulting, Inc. in the first quarter of 2012.
Several investor advisory publications and bloggers are using Cannabis Science as an example, saying MMJ-related stocks are altogether too risky for investors.
However, we feel this is too simplistic.
While the stock market itself is inherently risky, and due to legal factors MMJ-related stocks are even more so, some medical cannabis companies may be worth looking into. The key is to find companies with growing revenues in ancillary industries that do not depend entirely on FDA or other federal approval to continue.
A complaint filed by one marijuana legalization campaign against another in Ohio was dismissed unanimously [click to continue...]
Kyle Kingsley, MD, is hoping he’s found a way to expand his cannabis cultivation company [click to continue...]
A quartet of recreational cannabis shops in Washington State wrongly sold marijuana to minors in [click to continue...]
Yet another lawsuit has been filed in Illinois over the licensing process in the state’s [click to continue...]
Medical cannabis apparently isn’t socially acceptable in Connecticut. At least, not by Facebook. A marketing [click to continue...]
Former state Senate Minority Leader Eric Kearney, a Democrat from Cincinnati, has been hired by [click to continue...]
The Texas Legislature has sent a bill allowing CBD treatments for some epilepsy patients to [click to continue...]
Just a week after one legislative committee fought to a standstill over Oregon’s medical cannabis [click to continue...]
One of several losing contenders in Illinois’ medical marijuana program has withdrawn a lawsuit it [click to continue...]
Vicente Sederberg LLP, perhaps one of the best known marijuana legal firms in the country, [click to continue...]
Nine people were arrested at five locations after an Arizona SWAT team raided a medical [click to continue...]
Denver marijuana cultivator Organic Greens was shot down in court on Friday by a district [click to continue...]
Medical marijuana dispensary license applicants in Massachusetts will be judged on their own merits under [click to continue...]
The U.S. Food and Drug Administration has ruled that cannabidiol products don’t fit under the [click to continue...]